Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.
Smallpox virus (variola) poses a significant threat as an agent of bioterrorism. To mitigate this risk, antiviral drugs and an improved vaccine are urgently needed. Satisfactory demonstration of protective efficacy against authentic variola will require development of an animal model in which variola produces a disease course with features consistent with human smallpox. Toward this end, cynomolgus macaques were exposed to several variola strains through aerosol and/or i.v. routes. Two strains, Harper and India 7124, produced uniform acute lethality when inoculated i.v. in high doses (10(9) plaque-forming units). Lower doses resulted in less fulminant, systemic disease and lower mortality. Animals that died had profound leukocytosis, thrombocytopenia, and elevated serum creatinine levels. After inoculation, variola was disseminated by means of a monocytic cell-associated viremia. Distribution of viral antigens by immunohistochemistry correlated with the presence of replicating viral particles demonstrated by electron microscopy and pathology in the lymphoid tissues, skin, oral mucosa, gastrointestinal tract, reproductive system, and liver. These particles resembled those seen in human smallpox. High viral burdens in target tissues were associated with organ dysfunction and multisystem failure. Evidence of coagulation cascade activation (D dimers) corroborated histologic evidence of hemorrhagic diathesis. Depletion of T cell-dependent areas of lymphoid tissues occurred, probably as a consequence of bystander apoptotic mechanisms initiated by infected macrophages. Elaboration of cytokines, including IL-6 and IFN-gamma, contribute to a cytokine storm formerly known as "toxemia." A more precise understanding of disease pathogenesis should provide targets for therapeutic intervention, to be used alone or in combination with inhibitors of variola virus replication.
Headquarters, U.S. Army Research Institute of Infectious Diseases, Frederick, MD 21702, USA. peter.jahrling@us.army.mil
Peter B
PB
Jahrling
Lisa E
LE
Hensley
Mark J
MJ
Martinez
James W
JW
Leduc
Kathleen H
KH
Rubins
David A
DA
Relman
John W
JW
Huggins
D000818:Animals; D018925:Chemokines / Q000096:biosynthesis; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006801:Humans; D008252:Macaca fascicularis; D012899:Smallpox / Q000209:etiology* / Q000276:immunology / Q000473:pathology / Q000821:virology; D013045:Species Specificity; D012901:Variola virus / Q000302:isolation & purification / Q000472:pathogenicity
D018925:Chemokines; D016207:Cytokines; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D